Name: TLR7/8 agonist 13
Brand: TargetMol
SKU: T212528
Rating: 4.5 (1 reviews)

规格

价格

库存

数量

10 mg

待询

10-14周

50 mg

待询

10-14周

产品介绍

生物活性

产品描述	TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (with a lowest effective concentration (LEC) [hTLR7] of 1.6 μM) and TLR8 (LEC [hTLR8] of 1.6 μM). It acts on human peripheral blood mononuclear cells (hPBMC) with agonistic activity (LEC [hPBMC] = 0.5 μM). In mice and cynomolgus monkeys, TLR7/8 agonist 13 induces endogenous IFNα, activates myeloid dendritic cells and monocytes, promoting their differentiation towards a TH1 phenotype. In chronic AAV-HBV mouse models, it reduces viral load and HBV surface antigen levels. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, facilitating the response of HBV antigen-specific CD8 T cells. This compound is useful for hepatitis B virus research.
体外活性	TLR7/8 agonist 13 (Compound 50 d) 诱导 PBMCs 产生 IFNα、IFNγ、IL-12p40、IL-12p70和TNF-α。
体内活性	TLR7/8 agonist 13 (Compound 50 d) (1-50 mg/kg，口服，一次) 在 C57Bl/6 小鼠模型中引发 IFNα、TH1 和髓系反应。TLR7/8 agonist 13 (5 mg/kg，口服，每周一次，8 周) 通过两种非细胞毒性机制在 AAV-HBV C57Bl/6 小鼠模型中减少 HBsAg 的分泌和降低 HBV 病毒载量。TLR7/8 agonist 13 (3-30 mg/kg，口服，一次) 在食蟹猴中促进内源性 IFNα 的产生，同时活化髓系树突状细胞和单核细胞，促进其向 TH1 表型转变。